Recent Finacing
Recent Raise
Genenta Science develops ex-vivo lentiviral HSC gene therapies that program autologous tumor-infiltrating monocytes/macrophages to deliver localized interferon-alpha, advancing Phase I/II trials in multiple myeloma and glioblastoma.
